Novel approaches to support therapeutic development in ultra-rare cancers
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you have a novel cancer treatment approach for ultra-rare indications, FDA is actively seeking proposals to de-risk development in markets where traditional funding is scarce.
Report stale or inaccurate summary
What this is
This FDA-administered program (CFDA 93.103) seeks to fund novel therapeutic development specifically targeting ultra-rare cancers—oncologic conditions affecting extremely small patient populations where traditional drug development economics are challenging. Applicants should expect this to support early-stage research, clinical pathway planning, and innovative approaches that accelerate therapeutic options for patients with these neglected cancer types. The exact award amount and application deadline are not yet fully specified, so early monitoring is recommended.
Who can apply
Eligibility criteria are not yet specified in the posted opportunity. Confirm directly with FDA/HHS before investing application effort. CFDA 93.103 typically supports biomedical research entities including small businesses, nonprofits, and academic institutions, but verify specific restrictions and matching requirements.
Topics: ultra-rare cancer · therapeutic development · oncology · orphan disease · clinical pathway · FDA funding
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.